Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221863 | 0.87 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30612667 | 0.82 | ALDH1A1 (0.57) | ESR1LMNACYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL8412933 | 0.79 | KMT2A (0.42) | ESR1LMNACYP1A2CYP3A4POLB | |
| SCHEMBL87450 | 0.78 | CA1 (0.83) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4252766 | 0.77 | KMT2A (0.62) | ESR1ESR2LMNAHPGDALDH1A1 | |
| SCHEMBL23396864 | 0.77 | MMP12 (0.53) | POLBHPGDALDH1A1L3MBTL1HSP90AA1 | |
| SCHEMBL7746905 | 0.76 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21440358 | 0.76 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29504635 | 0.76 | CA1 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30271267 | 0.76 | CA1 (0.79) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-12-05 | — | — | US | disclosed |
| WO-2024172631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | 주식회사 카나프테라퓨틱스 | 2024-08-22 | — | — | WO | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11932635-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| EP-0190265-B1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0190265-A4 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1987-07-09 | — | — | EP | disclosed |
| US-4657919-A | CARDIOVASCULAR DISORDERS | E. I. DU PONT DE NEMOURS & CO. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0190265-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1986-08-13 | — | — | EP | disclosed |
| WO-1986001202-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-02-27 | — | — | WO | disclosed |
| US-4555517-A | Pyridone esters as inotropic agents | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CA12 1764/4885CA1 2822/4885CA2 3842/4885 |
| US-11932635-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | CA12 1764/4885CA1 2822/4885CA2 3842/4885 |
| US-20250051320-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CA12 1764/4885CA1 2822/4885CA2 3842/4885 |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | SOS1, RAC1, SOS2 | CA12 4739/4885CA1 4285/4885CA2 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.